Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Curis Inc CRIS

Healthcare Biotechnology
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK... see more

Recent & Breaking News (NDAQ:CRIS)

Curis to Present at the Jefferies Healthcare Conference

GlobeNewswire June 1, 2017

Research Reports Initiation on Biotech Stocks -- Corcept Therapeutics, Curis, OvaScience, and Vanda Pharma

PR Newswire May 30, 2017

Curis Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting

GlobeNewswire May 25, 2017

Investor Network: Curis, Inc. to Host Earnings Call

Accesswire May 4, 2017

Curis Reports First Quarter 2017 Financial Results

GlobeNewswire May 4, 2017

Curis to Release First Quarter 2017 Financial Results and Hold Conference Call on May 4, 2017

GlobeNewswire April 28, 2017

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire April 5, 2017

Curis to Present Preclinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Annual Meeting

GlobeNewswire March 30, 2017

Curis to Present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference

GlobeNewswire March 16, 2017

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  March 9, 2017

Research Reports Initiation on Biotech Stocks -- Alnylam Pharma, INSYS Therapeutics, Curis, and GenVec

PR Newswire March 9, 2017

Curis Reports Fourth Quarter and Year-End 2016 Financial Results

GlobeNewswire March 9, 2017

Curis to Release Fourth Quarter and Year End 2016 Financial Results and Hold Conference Call on March 9, 2017

GlobeNewswire March 7, 2017

Curis to Present at the Cowen and Company 37th Annual Health Care Conference

GlobeNewswire March 1, 2017

Curis to Present at the 2017 RBC Capital Markets Global Healthcare Conference

GlobeNewswire February 17, 2017

Technical Reports on Biotech Stocks -- Halozyme Therapeutics, Keryx Biopharma, Curis, and Agios Pharma

PR Newswire January 12, 2017

Curis and Aurigene Extend Exclusivity Period of Immuno-Oncology and Precision Oncology Collaboration

GlobeNewswire January 9, 2017

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire January 6, 2017

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Business Wire December 21, 2016

Biotech Stocks Head Into 2017 With Clinical Developments That Could Lead to Growth and Added Value

PR Newswire December 21, 2016